HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cai, W. Articles by Chen, X. Search for Related Content PubMed PubMed Citation Articles by Cai, W. Articles by Chen, X.

A Thiol-Reactive ¹⁸F-Labeling Agent, N-[2-(4-¹⁸F-Fluorobenzamido)Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of _vß₃ Integrin Expression

Molecular Imaging Program at Stanford (MIPS) and Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford, California

Correspondence: For correspondence or reprints contact: Xiaoyuan Chen, PhD, Molecular Imaging Program at Stanford (MIPS) and Bio-X Program, Department of Radiology, Stanford University School of Medicine, 1201 Welch Rd., Room P095, Stanford, CA 94305-5484. E-mail: shawchen{at}stanford.edu

The cell adhesion molecule integrin _vß₃ plays a key role in tumor angiogenesis and metastasis. A series of ¹⁸F-labeled RGD peptides have been developed for PET of integrin expression based on primary amine-reactive prosthetic groups. In this study we introduced a new method of labeling RGD peptides through a thiol-reactive synthon, N-[2-(4-¹⁸F-fluorobenzamido)ethyl]maleimide (¹⁸F-FBEM). Methods: ¹⁸F-FBEM was synthesized by coupling N-succinimidyl 4-¹⁸F-fluorobenzoate (¹⁸F-SFB) with N-(2-aminoethyl)maleimide. After high-pressure liquid chromatography purification, it was allowed to react with thiolated RGD peptides, and the resulting tracers were subjected to receptor-binding assay, in vivo metabolic stability assessment, biodistribution, and microPET studies in murine xenograft models. Results: Conjugation of monomeric and dimeric sulfhydryl-RGD peptides with ¹⁸F-FBEM was achieved in high yields (85% ± 5% nondecay-corrected on the basis of ¹⁸F-FBEM). The radiochemical purity of the ¹⁸F-labeled peptides was >98% and the specific activity was 100150 TBq/mmol. Noninvasive microPET and direct tissue sampling experiments demonstrated that both ¹⁸F-FBEM-SRGD (RGD monomer) and ¹⁸F-FBEM-SRGD2 (RGD dimer) had integrin-specific tumor uptake in subcutaneous U87MG glioma and orthotopic MDA-MB-435 breast cancer xenografts. Conclusion: The new tracer ¹⁸F-FBEM-SRGD2 was synthesized with high specific activity via ¹⁸F-FBEM and the tracer exhibited high receptor-binding affinity, tumor-targeting efficacy, metabolic stability, as well as favorable in vivo pharmacokinetics. The new synthon ¹⁸F-FBEM developed in this study will also be useful for radiolabeling of other thiolated biomolecules.

Key Words: thiol-reactive synthon • ¹⁸F-FBEM • microPET • ¹⁸F labeling • integrin _vß₃

Related articles in JNM:

This Month in JNM

JNM 2006 47: 11a-12a. [Full Text]  

This article has been cited by other articles:

				W. Cai and X. Chen Multimodality Molecular Imaging of Tumor Angiogenesis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S. [Abstract] [Full Text] [PDF]

				Z.-B. Li, Z. Wu, K. Chen, E. K. Ryu, and X. Chen 18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging J. Nucl. Med., March 1, 2008; 49(3): 453 - 461. [Abstract] [Full Text] [PDF]

				W. Cai, K. Chen, Z.-B. Li, S. S. Gambhir, and X. Chen Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature J. Nucl. Med., November 1, 2007; 48(11): 1862 - 1870. [Abstract] [Full Text] [PDF]

				Z. Wu, Z.-B. Li, K. Chen, W. Cai, L. He, F. T. Chin, F. Li, and X. Chen microPET of Tumor Integrin {alpha}v{beta}3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) J. Nucl. Med., September 1, 2007; 48(9): 1536 - 1544. [Abstract] [Full Text] [PDF]

				R. Rossin, D. Berndorff, M. Friebe, L. M. Dinkelborg, and M. J. Welch Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin J. Nucl. Med., July 1, 2007; 48(7): 1172 - 1179. [Abstract] [Full Text] [PDF]

				Z.-b. Li, W. Cai, Q. Cao, K. Chen, Z. Wu, L. He, and X. Chen 64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor {alpha}v{beta}3 Integrin Expression J. Nucl. Med., July 1, 2007; 48(7): 1162 - 1171. [Abstract] [Full Text] [PDF]

				W. Cai, T. Olafsen, X. Zhang, Q. Cao, S. S. Gambhir, L. E. Williams, A. M. Wu, and X. Chen PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an 18F-Labeled T84.66 Anti-Carcinoembryonic Antigen Diabody J. Nucl. Med., February 1, 2007; 48(2): 304 - 310. [Abstract] [Full Text] [PDF]

				W. Cai, J. Rao, S. S. Gambhir, and X. Chen How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther., November 1, 2006; 5(11): 2624 - 2633. [Abstract] [Full Text] [PDF]

				W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3 Cancer Res., October 1, 2006; 66(19): 9673 - 9681. [Abstract] [Full Text] [PDF]